4.7 Article

Perceived helpfulness of treatment for specific phobia: Findings from the World Mental Health Surveys

Journal

JOURNAL OF AFFECTIVE DISORDERS
Volume 288, Issue -, Pages 199-209

Publisher

ELSEVIER
DOI: 10.1016/j.jad.2021.04.001

Keywords

Helpfulness of treatment; Simple phobia; Specific phobia; World Mental Health Surveys

Funding

  1. United States National Institute of Mental Health (NIMH) [R01 MH070884]
  2. John D. and Catherine T. MacArthur Foundation
  3. Pfizer Foundation
  4. United States Public Health Service [R13-MH066849, R01-MH069864, R01 DA016558]
  5. Fogarty International Center [FIRCA R03-TW006481]
  6. Pan American Health Organization
  7. Eli Lilly and Company
  8. Ortho-McNeil Pharmaceutical Inc.
  9. Bristol-Myers Squibb
  10. Argentinian Ministry of Health (Ministerio de Salud de la Nacion) [2002-17270/13 5]
  11. State of Sao Paulo Research Foundation (FAPESP) [03/00204-3]
  12. Ministry of Health
  13. National Center for Public Health Protection
  14. Ministry of Health and European Economic Area Grants
  15. Ministry of Social Protection
  16. European Commission [QLG5-1999-01042, SANCO 2004123, EAHC 20081308]
  17. Fondo de Investigacion Sanitaria, Instituto de Salud Carlos III, Spain [FIS 00/0028]
  18. Ministerio de Ciencia y Tecnologia, Spain [SAF 2000-158-CE]
  19. Generalitat de Catalunya [2017 SGR 452, 2014 SGR 748]
  20. Instituto de Salud Carlos III [CIBER CB06/02/0046, RETICS RD06/0011 REM-TAP]
  21. GlaxoSmithKline
  22. Iraqi IMHS team
  23. Japanese Fund through United Nations Development Group Iraq Trust Fund (UNDG ITF)
  24. European Fund through United Nations Development Group Iraq Trust Fund (UNDG ITF)
  25. Japan Ministry of Health, Labour and Welfare [H13-SHOGAI-023, H14-TOKUBETSU-026, H16KOKORO-013, H25-SEISHIN-IPPAN-006]
  26. Lebanese Ministry of Public Health
  27. WHO (Lebanon)
  28. National Institute of Health/Fogarty International Center [R03 TW006481-01]
  29. Algorithm
  30. AstraZeneca
  31. National Institute of Psychiatry Ramon de la Fuente [INPRFMDIES 4280]
  32. National Council on Science and Technology [CONACyT-G30544-H]
  33. Pan American Health Organization (PAHO)
  34. New Zealand Ministry of Health
  35. Health Research Council
  36. WHO (Geneva)
  37. WHO (Nigeria)
  38. Federal Ministry of Health, Abuja, Nigeria
  39. Health & Social Care Research & Development Division of the Public Health Agency
  40. Polish project Epidemiology of Mental Health and Access to Care -EZOP Project [PL 0256]
  41. National Institute of Health of the Ministry of Health of Peru
  42. European Economic Area Financial Mechanism
  43. Polish Ministry of Health
  44. Champalimaud Foundation
  45. Foundation for Science and Technology (FCT)
  46. Ministry of Public Health
  47. Eli Lilly Romania SRL
  48. Saudi Basic Industries Corporation (SABIC), King Abdulaziz City for Science and Technology (KACST), Ministry of Health (Saudi Arabia)
  49. King Saud University
  50. Ministry of Economy and Planning, General Authority for Statistics
  51. Shenzhen Bureau of Health
  52. Shenzhen Bureau of Science, Technology, and Information
  53. Regional Health Authorities of Murcia (Servicio Murciano de Salud and Consejeria de Sanidad y Politica Social)
  54. Fundaci 'on para la Formaci 'on e Investigaci 'on Sanitarias (FFIS) of Murcia
  55. National Institute of Mental Health (NIMH) [U01-MH60220]
  56. National Institute of Drug Abuse (NIDA)
  57. Substance Abuse and Mental Health Services Administration (SAMHSA)
  58. Robert Wood Johnson Foundation (RWJF) [044708]
  59. John W. Alden Trust
  60. King Faisal Specialist Hospital and Research Center
  61. Center for Excellence on Research in Mental Health (CES University)
  62. Benta
  63. Bella Pharma
  64. Eli Lilly
  65. Glaxo Smith Kline
  66. Lundbeck
  67. Novartis
  68. OmniPharma
  69. Pfizer
  70. Phenicia
  71. Servier
  72. UPO
  73. Alcohol Advisory Council
  74. Norwegian Financial Mechanism
  75. Gulbenkian Foundation

Ask authors/readers for more resources

The study found that while a significant number of respondents reported receiving helpful treatment for specific phobias, only a small proportion persisted in seeking help from multiple professionals. Patient persistence in help-seeking after unsuccessful treatments could potentially increase the effectiveness of specific phobia treatment, but further research on barriers to help-seeking persistence is needed.
Background: Although randomized trials show that specific phobia treatments can be effective, it is unclear whether patients experience treatment as helpful in clinical practice. We investigated this issue by assessing perceived treatment helpfulness for specific phobia in a cross-national epidemiological survey. Methods: Cross-sectional population-based WHO World Mental Health (WMH) surveys in 24 countries (n=112,507) assessed lifetime specific phobia. Respondents who met lifetime criteria were asked whether they ever received treatment they considered helpful and the number of professionals seen up to the time of receiving helpful treatment. Discrete-event survival analysis was used to calculate conditional-cumulative probabilities of obtaining helpful treatment across number of professionals seen and of persisting in help-seeking after prior unhelpful treatment. Results: 23.0% of respondents reported receiving helpful treatment from the first professional seen, whereas cumulative probability of receiving helpful treatment was 85.7% after seeing up to 9 professionals. However, only 14.7% of patients persisted in seeing up to 9 professionals, resulting in the proportion of patients ever receiving helpful treatment (47.5%) being much lower than it could have been with persistence in help-seeking. Few predictors were found either of perceived helpfulness or of persistence in help-seeking after earlier unhelpful treatments. Limitations: Retrospective recall and lack of information about either types of treatments received or objective symptomatic improvements limit results. Conclusions: Despite these limitations, results suggest that helpfulness of specific phobia treatment could be increased, perhaps substantially, by increasing patient persistence in help-seeking after earlier unhelpful treatments. Improved understanding is needed of barriers to help-seeking persistence.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available